Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIR-T GD2
- Development stage
- Preclinical
- Lead developer
- Angeles Therapeutics
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
SIR-T GD2 is a preclinical-stage cell therapy candidate developed by Angeles Therapeutics for the treatment of GD2-positive malignancies. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR) platform, which engineers T cells to express a receptor that mimics the natural T-cell receptor (TCR) complex signaling architecture, potentially offering improved safety and efficacy over traditional Chimeric Antigen Receptor (CAR) designs. SIR-T GD2 specifically targets the disialoganglioside GD2, a tumor-associated antigen frequently overexpressed in neuroblastoma, osteosarcoma, and other solid tumors.
- Other names
- SIR-T GD2
02
Targets
GD2
Beyond the preview
Go deeper on SIR-T GD2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIR-T GD2.